Skip to main content Accessibility help
×
Home

P-1090 - Combination of Agomelatine and Bupropion for Treatment-resistant Depression: a Case Series

  • K.G. Kahl (a1), C. Eberlein (a1) and H. Frieling (a1)

Abstract

Introduction

Many patients with major depressive disorder fail to achieve remission with standard antidepressant therapy. Current options for the management of treatment resistant depression (TRD) comprise dose optimization, switching within or between drug classes, augmenting with other drugs and combination strategies. However, the application of combination treatment may be limited by adverse side effects.

Method

From February 2010 to February 2011, twelve inpatients with TRD were retrospectively identified as being treated with a combination of agomelatine and bupropion after discontinuation of former antidepressant treatment. Mean doses of agomelatine at the end of treatment were 47.9 ± 7.2 mg/d, and bupropion 325 ± 86.6 mg/d. Intensity of depressive symptoms was routinely assessed using Beck's Depression Inventory-2. Response was defined as decrease of BDI sum score by 50%, and remission as BDI sum score below 13. Metabolic parameters and adverse side effects were routinely measured. Statistical analysis was performed using paired t-test and repeated measurements ANOVA with degree of TRD as covariate, and unpaired t-test for gender comparisons.

Results

Eight patients showed response, and seven reached remission after 6–8 weeks of inpatient treatment. This effect was independent of the degree of TRD.

Discussion

How to continue antidepressive treatment after an initially unsuccessful trial is a vital question. However, guidance as to which option is to be favoured remains limited. In particular, the use of antidepressant combinations to address TRD is understudied. We have shown that combination treatment with agomelatine/bupropion in TRD may lead to significant symptom relief. Future randomized controlled trials are needed to confirm our results.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      P-1090 - Combination of Agomelatine and Bupropion for Treatment-resistant Depression: a Case Series
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      P-1090 - Combination of Agomelatine and Bupropion for Treatment-resistant Depression: a Case Series
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      P-1090 - Combination of Agomelatine and Bupropion for Treatment-resistant Depression: a Case Series
      Available formats
      ×

Copyright

P-1090 - Combination of Agomelatine and Bupropion for Treatment-resistant Depression: a Case Series

  • K.G. Kahl (a1), C. Eberlein (a1) and H. Frieling (a1)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

P-1090 - Combination of Agomelatine and Bupropion for Treatment-resistant Depression: a Case Series

  • K.G. Kahl (a1), C. Eberlein (a1) and H. Frieling (a1)
Submit a response

Comments

No Comments have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *